ArticleScientific reports2026
Integrated HPLC and STOCSY reveal two new lanaroft type biflavonoids from Selaginella plants.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dereplicating by standalone LC-MS remains challenging for low-abundance biflavonoids (BFVs) in Selaginella extracts, as structural isomers share identical molecular weights, possess diverse interflavonoid linkages, and exhibit highly similar fragmentation patterns, thereby increasing the risk of misannotation. Here, an integrated high-performance liquid chromatography (HPLC)-statistical total correlation spectroscopy (STOCSY) workflow was introduced to enable cross-identification of BFVs across partially resolved fractions in two Selaginella extracts, namely Selaginella plana, and S. padangensis. In the workflow, initial screening of crude extracts was performed by matching HPLC retention time against an in-house BFV library. Subsequent STOCSY analysis of partially resolved fractions obtained from S. plana, enabled orthogonal validation of known BFVs. Crucially, unmatched correlated signals guided the selection of target fractions for purification and characterization, leading to the discovery of planaflavone A, an undescribed lanaroft-type BFV. A comparable HPLC RT observed in S. padangensis further directed the isolation of an additional lanaroft-type BFV, padangeflavone A. Collectively, this integrative workflow accelerated compound discovery by enabling discrimination of BFVs with diverse linkage types that are indistinguishable by LC–MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.